Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
Status: ENROLLING_BY_INVITATION
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
Interventions: DRUG: SHR6390|DRUG: placebo
Sponsor: Jiangsu HengRui Medicine Co., Ltd.